Just out in ⁦Clinical Cancer Research⁩. Congrats to all the authors on this tremendous group effort. ⁦Anwaar Saeed⁩ ⁦Razelle Kurzrock, MD⁩ ⁦Andres Cervantes⁩ pubmed.ncbi.nlm.nih.gov/37982822/

linkedin.com/posts/precisio…

#GI24 ASCO So proud of talented Maysa Vilbert for elite pooled analysis of frontline ESCC chemo + IO 😇 > better OS significance with higher CPS group > in contrast to prior negative results from pooled analysis in adenocarcinoma, p value in CPS <10 is significant for ESCC ✨

In a meta-analysis of 10 studies by Michelin et al, published on ESMO Open, T-DXd was found associated with relevant intracranial activity among patients with breast cancer brain metastases (IC-ORR 61%, mPFS 15 months). Read the article here: esmoopen.com/article/S2059-…

One of the most critical features of novel ADCs is their emerging intracranial activity. Few treatments in oncology allow to achieve >50% intracranial response rates, with durable (PFS 15 months!!) efficacy. Interesting meta-analysis - follow ESMO Open for more! 👇

🔥off the press: clinical & biomarker results of CAMILLA CRC cohort, positive outcome w differential advantage in RAS wild-type population. Insightful spatial transcriptomic findings laying the foundation for ongoing phase III STELLAR 303 trial ✨UPMC Hillman Cancer Center OncoAlert

⁦Anwaar Saeed⁩ #SantaMonica #LA when #SOGO24 team member meets with #TTLC ⁦IASLC⁩ member on their way back #Oncology ⁦Ludimila Cavalcante⁩ #phaseI #WomeninOncology

Presenting our data in Ewing sarcoma at #ASCO24 Elite work by Maysa Vilbert Jonathan N. Priantti Meta-analysis evaluating second line TKIs in Ewing Sarcoma Meta Analysis Academy UVA

⁦ASCO⁩ Women are under-represented in abstract presentation in GI Oncology #ASCO24 Dr. Rachmaninov Shroff ⁦Hematology & Oncology Women Physicians Group—HOWPG⁩ ⁦Toni Choueiri, MD⁩ ⁦@noha_soror⁩ ⁦Raymond Wadlow MD⁩ ⁦Anwaar Saeed⁩ ⁦Ludimila Cavalcante⁩ ⁦Rachna⁩

Hot off the press! Our meta-analysis supports EGFR-TKI rechallenge as a valid strategy in metastatic #NSCLC. This may offer an alternative to overcoming treatment access barriers in low- and middle-income countries. mdpi.com/2870852 JPM_MDPI

Just released! Our meta-analysis underscores the importance of increasing awareness about lorlatinib-related neurocognitive adverse events (NAEs) to improve their recognition and reporting, thereby enhancing NSCLC patients' quality of life. Link: mdpi.com/2072-6694/16/1…

New #JITC article: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2) jitc.bmj.com/content/12/8/e… Diwakar Davar, M.D.

Davoceticept as monotherapy and in combination with pembrolizumab in advanced solid tumors Journal for ImmunoTherapy of Cancer Diwakar Davar, M.D. Ludimila Cavalcante mark voskoboynik Rachel E. Sanborn, MD Justin Gainor #Cancer #OncoDaily #Oncology #CancerCare #CancerResearch oncodaily.com/119169.html

New #JITC case report: Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab bit.ly/3SSsHjF Ludimila Cavalcante

Here’s a closer look at “Case Report of Fatal Immune-mediated Myocarditis Following Treatment with Davoceticept (ALPN-202), a PD-L1-dependent CD28 Costimulator & Dual PD-L1/CTLA-4 Checkpoint Inhibitor, in Combination w/Pembrolizumab” from Ludimila Cavalcante at UVA Comprehensive Cancer Center and

Check out this new systematic review and meta-analysis discussing #AntibodyDrugConjugates in patients with advanced/metastatic HER2-low-expressing #BreastCancer. 🔓pubmed.ncbi.nlm.nih.gov/39574495/ ✍️Maysa Vilbert Paolo Tarantino Evandro de Azambuja, MD, PhD Ludimila Cavalcante #ADCs #HER2low

Patients with refractory Ewing Sarcoma now have a clinical trial option ⁦UVA Health⁩ linkedin.com/posts/ludimila…

Our KM-reconstructed Meta-analysis showing a significant OS benefit of Neoadjuvant chemotherapy in angiosarcoma. #ctos2025 Clinical trials are still needed to standardize therapy. Exceptional work by Isabella Michelon Anderson Ruiz Simoes Wellington Carneiro Meta Analysis Academy UVA Health